Interventions for Tuberculosis Control and Elimination 2002

165. Ahn HC, Yang JH, Lee HB, Rhee YK, Lee YC. Effect of combined therapy of
oral anti-tubercular agents on theophylline pharmacokinetics.
Dis 2000; 4: 784-7.
Int J Tuberc Lung
166. Judd FK, Mijch AM, Cockram A, Norman TR. Isoniazid and anti-depressants:
is it a cause for concern? Intern Clin Psychopharmacol 1994; 9: 123-5.
167. Malek-Ahmadi P, Chavez M, Contreras SA. Coadministration of isoniazid and
antidepressant drugs. (Correspondence). J Clin Psychiatry 1996; 57: 550.
168. Gannon R, Pearsall W, Rowley R. Isoniazid, meperidine, and hypothension.
(Correspondence). Ann Intern Med 1983; 99: 415.
169. Morgan JP.
92: 434.
Isoniazid and levodopa. (Correspondence). Ann Intern Med 1980;
170. Mazze RI, Woodruff RE, Heerdt ME. Isoniazid-induced enflurane defluorination
in humans. Anesthesiology 1982; 57: 5-8.
171. Sensi P, Margalith P, Timbal MT. Rifomycin, a new antibiotic - preliminary
report. (Correspondence). Farmaco Ed Sci 1959; 14: 146-7.
172. Sensi P. A family of new antibiotics, the rifamycins. Res Prog Org Biol Chem
1964; 1: 338-421.
173. Oppolzer W, Prelog V, Sensi P. Konstitution des Rifamycins B und verwandter
Rifamycine. Experientia 1964; 20: 336-9.
174. Maggi N, Pasqualucci CR, Ballotta R, Sensi P. Rifampicin: a new orally active
rifamycin. Chemotherapia 1966; 11: 285-92.
175. Kenny MT, Strates B. Metabolism and pharmacokinetics of the antibiotic
rifampin. Drug Metabolism Rev 1981; 12: 159-218.
176. Telenti A. Genetics of drug resistant tuberculosis. Thorax 1998; 53: 793-7.
177. Miller LP, Crawford JT, Shinnick TM. The rpoB gene of Mycobacterium tuberculosis.
Antimicrob Agents Chemother 1994; 38: 805-11.
178. Telenti A, Lowrie D, Matter L, Imboden P, Cole S, Schopfer K, Marchesi F,
Colston MJ, Bodmer T. Detection of rifampicin-resistance mutations in
Mycobacterium tuberculosis. Lancet 1993; 341: 647-50.
179. Cole ST. Rifamycin resistance in mycobacteria. Res Microbiol 1996; 147: 48-52.
180. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinetics
1978; 3: 108-27.
181. Peloquin CA, Jaresko GS, Yong CL, Keung ACF, Bulpitt AE, Jelliffe RW.
Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide.
Antimicrob Agents Chemother 1997; 41: 2670-9.
182. Pähkla R, Lambert J, Ansko P, Winstanley P, Davies PDO, Kiivet RA.
Comparative bioavailability of three different preparations of rifampicin. J Clin
Pharm Ther 1999; 24: 219-25.
181